Your browser doesn't support javascript.
loading
Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial.
Palhano-Fontes, Fernanda; Barreto, Dayanna; Onias, Heloisa; Andrade, Katia C; Novaes, Morgana M; Pessoa, Jessica A; Mota-Rolim, Sergio A; Osório, Flávia L; Sanches, Rafael; Dos Santos, Rafael G; Tófoli, Luís Fernando; de Oliveira Silveira, Gabriela; Yonamine, Mauricio; Riba, Jordi; Santos, Francisco R; Silva-Junior, Antonio A; Alchieri, João C; Galvão-Coelho, Nicole L; Lobão-Soares, Bruno; Hallak, Jaime E C; Arcoverde, Emerson; Maia-de-Oliveira, João P; Araújo, Dráulio B.
Afiliação
  • Palhano-Fontes F; Brain Institute, Federal University of Rio Grande do Norte (UFRN),Natal/RN,Brazil.
  • Barreto D; Onofre Lopes University Hospital, UFRN,Natal/RN,Brazil.
  • Onias H; Brain Institute, Federal University of Rio Grande do Norte (UFRN),Natal/RN,Brazil.
  • Andrade KC; Brain Institute, Federal University of Rio Grande do Norte (UFRN),Natal/RN,Brazil.
  • Novaes MM; Brain Institute, Federal University of Rio Grande do Norte (UFRN),Natal/RN,Brazil.
  • Pessoa JA; Brain Institute, Federal University of Rio Grande do Norte (UFRN),Natal/RN,Brazil.
  • Mota-Rolim SA; Brain Institute, Federal University of Rio Grande do Norte (UFRN),Natal/RN,Brazil.
  • Osório FL; Department of Neurosciences and Behaviour,University of São Paulo (USP),Ribeirão Preto/SP,Brazil.
  • Sanches R; Department of Neurosciences and Behaviour,University of São Paulo (USP),Ribeirão Preto/SP,Brazil.
  • Dos Santos RG; Department of Neurosciences and Behaviour,University of São Paulo (USP),Ribeirão Preto/SP,Brazil.
  • Tófoli LF; Department of Medical Psychology and Psychiatry,University of Campinas,Campinas/SP,Brazil.
  • de Oliveira Silveira G; Department of Clinical Analysis and Toxicology,USP,São Paulo/SP,Brazil.
  • Yonamine M; Department of Clinical Analysis and Toxicology,USP,São Paulo/SP,Brazil.
  • Riba J; Sant Pau Institute of Biomedical Research,Barcelona,Spain.
  • Santos FR; Department of Pharmacy,UFRN,Natal/RN, -Brazil.
  • Silva-Junior AA; Department of Pharmacy,UFRN,Natal/RN, -Brazil.
  • Alchieri JC; Department of Psychology,UFRN,Natal/RN,Brazil.
  • Galvão-Coelho NL; National Institute of Science and Technology in Translational Medicine (INCT-TM),Ribeirão Preto/SP,Brazil.
  • Lobão-Soares B; National Institute of Science and Technology in Translational Medicine (INCT-TM),Ribeirão Preto/SP,Brazil.
  • Hallak JEC; Department of Neurosciences and Behaviour,University of São Paulo (USP),Ribeirão Preto/SP,Brazil.
  • Arcoverde E; Onofre Lopes University Hospital, UFRN,Natal/RN,Brazil.
  • Maia-de-Oliveira JP; Onofre Lopes University Hospital, UFRN,Natal/RN,Brazil.
  • Araújo DB; Brain Institute, Federal University of Rio Grande do Norte (UFRN),Natal/RN,Brazil.
Psychol Med ; 49(4): 655-663, 2019 03.
Article em En | MEDLINE | ID: mdl-29903051
BACKGROUND: Recent open-label trials show that psychedelics, such as ayahuasca, hold promise as fast-onset antidepressants in treatment-resistant depression. METHODS: To test the antidepressant effects of ayahuasca, we conducted a parallel-arm, double-blind randomized placebo-controlled trial in 29 patients with treatment-resistant depression. Patients received a single dose of either ayahuasca or placebo. We assessed changes in depression severity with the Montgomery-Åsberg Depression Rating Scale (MADRS) and the Hamilton Depression Rating scale at baseline, and at 1 (D1), 2 (D2), and 7 (D7) days after dosing. RESULTS: We observed significant antidepressant effects of ayahuasca when compared with placebo at all-time points. MADRS scores were significantly lower in the ayahuasca group compared with placebo at D1 and D2 (p = 0.04), and at D7 (p < 0.0001). Between-group effect sizes increased from D1 to D7 (D1: Cohen's d = 0.84; D2: Cohen's d = 0.84; D7: Cohen's d = 1.49). Response rates were high for both groups at D1 and D2, and significantly higher in the ayahuasca group at D7 (64% v. 27%; p = 0.04). Remission rate showed a trend toward significance at D7 (36% v. 7%, p = 0.054). CONCLUSIONS: To our knowledge, this is the first controlled trial to test a psychedelic substance in treatment-resistant depression. Overall, this study brings new evidence supporting the safety and therapeutic value of ayahuasca, dosed within an appropriate setting, to help treat depression. This study is registered at http://clinicaltrials.gov (NCT02914769).
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Banisteriopsis / Transtorno Depressivo Resistente a Tratamento / Alucinógenos / Fitoterapia / Antidepressivos Tipo de estudo: Clinical_trials Limite: Adult / Female / Humans / Male Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Banisteriopsis / Transtorno Depressivo Resistente a Tratamento / Alucinógenos / Fitoterapia / Antidepressivos Tipo de estudo: Clinical_trials Limite: Adult / Female / Humans / Male Idioma: En Ano de publicação: 2019 Tipo de documento: Article